ArticleJournal of translational medicine2024

Validation of the Meet-URO score in metastatic clear cell renal cell carcinoma patients receiving second or third-line tyrosine kinase inhibitors-immune checkpoint inhibitors combination therapy.

Sike He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.